Innoviva Debt to Equity Ratio 2004-2025 | INVA
Current and historical debt to equity ratio values for Innoviva (INVA) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Innoviva debt/equity for the three months ending June 30, 2025 was 0.80.
| Innoviva Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2025-06-30 |
$0.62B |
$0.72B |
0.87 |
| 2025-03-31 |
$0.61B |
$0.65B |
0.94 |
| 2024-12-31 |
$0.61B |
$0.69B |
0.88 |
| 2024-09-30 |
$0.56B |
$0.67B |
0.84 |
| 2024-06-30 |
$0.56B |
$0.67B |
0.84 |
| 2024-03-31 |
$0.56B |
$0.70B |
0.80 |
| 2023-12-31 |
$0.57B |
$0.68B |
0.84 |
| 2023-09-30 |
$0.56B |
$0.63B |
0.89 |
| 2023-06-30 |
$0.56B |
$0.56B |
1.02 |
| 2023-03-31 |
$0.57B |
$0.56B |
1.01 |
| 2022-12-31 |
$0.67B |
$0.57B |
1.18 |
| 2022-09-30 |
$0.69B |
$0.64B |
1.07 |
| 2022-06-30 |
$0.57B |
$0.57B |
1.01 |
| 2022-03-31 |
$0.56B |
$0.55B |
1.01 |
| 2021-12-31 |
$0.40B |
$0.53B |
0.76 |
| 2021-09-30 |
$0.40B |
$0.49B |
0.80 |
| 2021-06-30 |
$0.40B |
$0.39B |
1.00 |
| 2021-03-31 |
$0.39B |
$0.70B |
0.56 |
| 2020-12-31 |
$0.39B |
$0.61B |
0.64 |
| 2020-09-30 |
$0.39B |
$0.54B |
0.72 |
| 2020-06-30 |
$0.39B |
$0.49B |
0.79 |
| 2020-03-31 |
$0.38B |
$0.41B |
0.94 |
| 2019-12-31 |
$0.38B |
$0.34B |
1.12 |
| 2019-09-30 |
$0.39B |
$0.28B |
1.38 |
| 2019-06-30 |
$0.40B |
$0.25B |
1.60 |
| 2019-03-31 |
$0.39B |
$0.20B |
1.95 |
| 2018-12-31 |
$0.39B |
$0.16B |
2.45 |
| 2018-09-30 |
$0.39B |
$-0.11B |
-3.57 |
| 2018-06-30 |
$0.49B |
$-0.16B |
-3.18 |
| 2018-03-31 |
$0.49B |
$-0.21B |
-2.30 |
| 2017-12-31 |
$0.61B |
$-0.24B |
-2.51 |
| 2017-09-30 |
$0.61B |
$-0.22B |
-2.75 |
| 2017-06-30 |
$0.67B |
$-0.30B |
-2.25 |
| 2017-03-31 |
$0.73B |
$-0.33B |
-2.17 |
| 2016-12-31 |
$0.73B |
$-0.35B |
-2.07 |
| 2016-09-30 |
$0.74B |
$-0.37B |
-2.01 |
| 2016-06-30 |
$0.74B |
$-0.36B |
-2.04 |
| 2016-03-31 |
$0.75B |
$-0.36B |
-2.07 |
| 2015-12-31 |
$0.75B |
$-0.34B |
-2.19 |
| 2015-09-30 |
$0.76B |
$-0.32B |
-2.36 |
| 2015-06-30 |
$0.76B |
$-0.29B |
-2.57 |
| 2015-03-31 |
$0.75B |
$-0.26B |
-2.88 |
| 2014-12-31 |
$0.75B |
$-0.22B |
-3.34 |
| 2014-09-30 |
$0.75B |
$-0.19B |
-3.87 |
| 2014-06-30 |
$0.79B |
$-0.19B |
-4.23 |
| 2014-03-31 |
$0.34B |
$0.26B |
1.30 |
| 2013-12-31 |
$0.38B |
$0.30B |
1.28 |
| 2013-09-30 |
$0.34B |
$0.33B |
1.02 |
| 2013-06-30 |
$0.51B |
$0.09B |
5.94 |
| 2013-03-31 |
$0.50B |
$0.09B |
5.46 |
| 2012-12-31 |
$0.21B |
$0.16B |
1.38 |
| 2012-09-30 |
$0.21B |
$0.17B |
1.22 |
| 2012-06-30 |
$0.21B |
$0.19B |
1.11 |
| 2012-03-31 |
$0.21B |
$0.01B |
34.51 |
| 2011-12-31 |
$0.35B |
$-0.09B |
-3.97 |
| 2011-09-30 |
$0.34B |
$-0.06B |
-5.79 |
| 2011-06-30 |
$0.34B |
$-0.04B |
-9.09 |
| 2011-03-31 |
$0.34B |
$-0.03B |
-12.33 |
| 2010-12-31 |
$0.35B |
$-0.02B |
-15.77 |
| 2010-09-30 |
$0.35B |
$-0.14B |
-2.51 |
| 2010-06-30 |
$0.36B |
$-0.13B |
-2.85 |
| 2010-03-31 |
$0.36B |
$-0.11B |
-3.21 |
| 2009-12-31 |
$0.37B |
$-0.19B |
-1.96 |
| 2009-09-30 |
$0.36B |
$-0.18B |
-2.05 |
| 2009-06-30 |
$0.37B |
$-0.16B |
-2.29 |
| 2009-03-31 |
$0.36B |
$-0.14B |
-2.49 |
| 2008-12-31 |
$0.37B |
$-0.14B |
-2.75 |
| 2008-09-30 |
$0.38B |
$-0.13B |
-3.04 |
| 2008-06-30 |
$0.39B |
$-0.11B |
-3.52 |
| 2008-03-31 |
$0.39B |
$-0.09B |
-4.31 |
| 2007-12-31 |
$0.23B |
$-0.07B |
-3.45 |
| 2007-09-30 |
$0.24B |
$-0.04B |
-5.86 |
| 2007-06-30 |
$0.22B |
$-0.02B |
-14.17 |
| 2007-03-31 |
$0.23B |
$0.02B |
11.17 |
| 2006-12-31 |
$0.20B |
$0.06B |
3.15 |
| 2006-09-30 |
$0.20B |
$0.09B |
2.11 |
| 2006-06-30 |
$0.19B |
$0.13B |
1.54 |
| 2006-03-31 |
$0.17B |
$0.16B |
1.08 |
| 2005-12-31 |
$0.17B |
$0.06B |
2.77 |
| 2005-09-30 |
$0.10B |
$0.10B |
1.01 |
| 2005-06-30 |
$0.10B |
$0.13B |
0.75 |
| 2005-03-31 |
$0.10B |
$0.16B |
0.61 |
| 2004-12-31 |
$0.10B |
$0.19B |
0.50 |
| 2004-09-30 |
$0.10B |
$0.11B |
0.90 |
| 2004-06-30 |
$0.00B |
|
0.00 |
| 2004-03-31 |
$0.00B |
|
0.00 |
| 2003-09-30 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$0.953B |
$0.331B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
